BioCardia, Inc. – NASDAQ:BCDA
BioCardia stock price today
$1.898
-0.56
-22.83%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
BioCardia stock price monthly change
-24.31%
month
BioCardia stock price quarterly change
-24.31%
quarter
BioCardia stock price yearly change
+261.76%
year
BioCardia key metrics
Market Cap | 8.98M |
Enterprise value | 29.38M |
P/E | -2.96 |
EV/Sales | 12.31 |
EV/EBITDA | -1.66 |
Price/Sales | 14.71 |
Price/Book | 7.17 |
PEG ratio | -0.27 |
EPS | -0.46 |
Revenue | 468K |
EBITDA | -10.15M |
Income | -10.33M |
Revenue Q/Q | -14.06% |
Revenue Y/Y | -65.48% |
Profit margin | -743.04% |
Oper. margin | -244.05% |
Gross margin | 0% |
EBIT margin | -244.05% |
EBITDA margin | -2169.44% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBioCardia stock price history
BioCardia stock forecast
BioCardia financial statements
| Jun 2023 | 43K | -3.42M | -7962.79% |
|---|---|---|---|
| Sep 2023 | 357K | -2.57M | -721.01% |
| Dec 2023 | 13K | -2.07M | -15938.46% |
| Mar 2024 | 55K | -2.26M | -4121.82% |
| 2025 | 700K | -19.1M | -2728.57% |
|---|---|---|---|
| 2026 | 5.7M | -19M | -333.33% |
| 2027 | 56.96M | 55.59M | 97.6% |
| 2028 | 185.92M | 29.65M | 15.95% |
Analysts Price target
Financials & Ratios estimates
| 2023-05-09 | -0.17 | -0.21 |
|---|
| Jun 2023 | 6389000 | 4.75M | 74.41% |
|---|---|---|---|
| Sep 2023 | 3747000 | 4.40M | 117.61% |
| Dec 2023 | 2987000 | 4.59M | 153.67% |
| Mar 2024 | 2679000 | 4.95M | 184.92% |
| Jun 2023 | -3.15M | -2K | 2.60M |
|---|---|---|---|
| Sep 2023 | -2.41M | 0 | -58K |
| Dec 2023 | -1.85M | 0 | 1.11M |
| Mar 2024 | -1.53M | 0 | 1.37M |
BioCardia alternative data
| Aug 2023 | 30 |
|---|---|
| Sep 2023 | 30 |
| Oct 2023 | 30 |
| Nov 2023 | 30 |
| Dec 2023 | 30 |
| Jan 2024 | 30 |
| Feb 2024 | 30 |
| Mar 2024 | 30 |
| Apr 2024 | 30 |
| May 2024 | 16 |
| Jun 2024 | 16 |
| Jul 2024 | 16 |
BioCardia other data
4.05%
-5.06%
of BCDA is owned by hedge funds
14
-11
1.03M
-1.29M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 129802 |
| Nov 2024 | 1350 | 0 |
| Dec 2024 | 1250 | 3257 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ALTMAN PETER director, officer.. | Common Stock | 1,000 | $2.06 | $2,060 | ||
Sale | GILLIS EDWARD M officer: Senior Vice President,.. | Common Stock | 3,257 | $2 | $6,514 | ||
Purchase | ALTMAN PETER director, officer.. | Common Stock | 250 | $2.22 | $555 | ||
Purchase | ALTMAN PETER director, officer.. | Common Stock | 1,350 | $1.87 | $2,525 | ||
Sale | FROST PHILLIP MD ET AL 10 percent owner | Common Stock | 129,802 | $0.43 | $55,815 | ||
Sale | FROST PHILLIP MD ET AL 10 percent owner | Common Stock | 129,802 | $0.43 | $55,815 | ||
Purchase | ALTMAN PETER director, officer.. | Common Stock | 4,000 | $0.87 | $3,484 | ||
Purchase | ALTMAN PETER director, officer.. | Common Stock | 6,200 | $1.6 | $9,920 | ||
Purchase | FROST PHILLIP MD ET AL director | Common Stock | 595,238 | $1.68 | $1,000,000 | ||
Purchase | FROST PHILLIP MD ET AL director | Common Stock | 595,238 | $1.68 | $1,000,000 |
| Patent |
|---|
Grant Filling date: 8 Jan 2014 Issue date: 14 Jun 2022 |
Application Filling date: 11 Sep 2021 Issue date: 2 Jun 2022 |
Application Filling date: 24 Jun 2021 Issue date: 14 Oct 2021 |
Grant Utility: Multi-directional steerable catheter Filling date: 27 Aug 2018 Issue date: 12 Oct 2021 |
Application METHODS OF MEASURING POTENTIAL FOR THERAPEUTIC POTENCY AND DEFINING DOSAGES FOR AUTOLOGOUS CELL THERAPIES Filling date: 30 Jul 2020 Issue date: 3 Jun 2021 |
Grant Filling date: 6 Oct 2015 Issue date: 29 Dec 2020 |
Application Filling date: 2 Sep 2020 Issue date: 24 Dec 2020 |
Grant Filling date: 9 Aug 2018 Issue date: 22 Sep 2020 |
Grant Filling date: 21 Apr 2014 Issue date: 28 Apr 2020 |
Application BONE MARROW DERIVED NEUROKININ-1 RECEPTOR POSITIVE (NK1R+) PRECURSOR CELLS FOR THERAPEUTIC APPLICATIONS Filling date: 26 Sep 2019 Issue date: 2 Apr 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Peter A. Altman (1967) Chief Executive Officer, Pres & Director | $379,990 |
| Mr. David McClung (1963) Chief Financial Officer | $317,750 |
-
What's the price of BioCardia stock today?
One share of BioCardia stock can currently be purchased for approximately $1.9.
-
When is BioCardia's next earnings date?
Unfortunately, BioCardia's (BCDA) next earnings date is currently unknown.
-
Does BioCardia pay dividends?
No, BioCardia does not pay dividends.
-
How much money does BioCardia make?
BioCardia has a market capitalization of 8.98M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 64.72% to 477K US dollars. BioCardia made a loss 11.57M US dollars in net income (profit) last year or -$0.21 on an earnings per share basis.
-
What is BioCardia's stock symbol?
BioCardia, Inc. is traded on the NASDAQ under the ticker symbol "BCDA".
-
What is BioCardia's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of BioCardia?
Shares of BioCardia can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BioCardia's key executives?
BioCardia's management team includes the following people:
- Dr. Peter A. Altman Chief Executive Officer, Pres & Director(age: 58, pay: $379,990)
- Mr. David McClung Chief Financial Officer(age: 62, pay: $317,750)
-
How many employees does BioCardia have?
As Jul 2024, BioCardia employs 16 workers, which is 47% less then previous quarter.
-
When BioCardia went public?
BioCardia, Inc. is publicly traded company for more then 28 years since IPO on 13 Nov 1996.
-
What is BioCardia's official website?
The official website for BioCardia is biocardia.com.
-
Where are BioCardia's headquarters?
BioCardia is headquartered at 320 Soquel Way, Sunnyvale, CA.
-
How can i contact BioCardia?
BioCardia's mailing address is 320 Soquel Way, Sunnyvale, CA and company can be reached via phone at +65 02260120.
BioCardia company profile:
BioCardia, Inc.
biocardia.comExchange:
NASDAQ
Full time employees:
16
Industry:
Biotechnology
Sector:
Healthcare
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
320 Soquel Way
Sunnyvale, CA 94085
Sunnyvale, CA 94085
CIK: 0000925741
ISIN: US09060U5074
CUSIP: 09060U507
